A notable example and a poster child of personalised oncology are PARP1/2 inhibitors (PARPi) that selectively kill HR‐deficient (HRD) cancer cells by preventing repair of DNA gaps or single‐strand breaks (SSBs) (Slade, 2020). Here, PARP1 is linked to cancer.